Skip to main content

Table 3 Subgroup analyses for the outcome of relapse-free survival

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups No. of studies HR (95% CI) I2 (P value)
Population
 Children 3 3.22 (1.68–6.18) 57.6% (0.10)
 Adult 4 1.69 (1.02–2.80) 69.5% (0.02)
Design
 Prospective 5 2.37 (1.12–5.01) 77.7% (< 0.01)
 Retrospective 5 2.71 (1.58–4.64) 73.5% (< 0.01)
Region
 Europe 5 2.38 (1.26–4.50) 83.5% (< 0.01)
 USA 3 2.87 (1.35–6.10) 56.7% (0.10)
 Asia 2 2.61 (0.66–10.40) 75.6% (0.04)
Detection method
 PCR 5 2.09 (1.07–4.08) 75.3% (< 0.01)
 FC 4 3.58 (1.73–7.40) 73.8% (< 0.01)
Adjustment
 Adjusted 7 2.50 (1.64–3.82) 64.4% (0.01)
 Crude 3 2.93 (0.81–10.64) 86.3% (< 0.01)